|Budget Amount *help
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|Outline of Final Research Achievements
Epigenetic modifications such as histone deacetylation are commonly related to tumor development and histone deacetylase (HDAC) inhibitors have been shown to be potential drugs for cancer treatment. Ky-2 is a novel HDAC inhibitor produced by a combination of the HDAC inhibitors TSA and TPX.
In the present study, we investigated the effectiveness of Ky-2 to induce cell cycle and apoptosis in oral squamous carcinoma cells. In addition, we examined the signaling pathway related to the cell cycle and apoptosis in Ky-2-treated oral squamous carcinoma cells.